# Lakeridge Health

#### Parenteral Nutrition Adult – Medical Directive

### Medical Advisory Committee Approved: 28SEPT2023

Harmonized

A printed copy of this document may not reflect the current, electronic version on Lakeridge Health's Intranet, 'The Wave.' Any copies of this document appearing in paper form should ALWAYS be checked against the electronic version prior to use.

### **Authorizing Prescriber(s)**

All Lakeridge Health (LH) Most Responsible Practitioners (MRP) who prescribe Parenteral Nutrition (PN) Therapy to LH patients.

#### Authorized to whom

Registered Dietitians (RD) employed at LH who have the knowledge, skill, and judgement as part of their scope of practice in the selection of PN or discontinuation of PN may implement the Medical Directive

Co-implementers: Nurses, laboratory technicians and pharmacists employed at LH may coimplement this Medical Directive

### **Patient Description / Population**

Adult admitted patients (18 years of age or older) who are not able to meet their nutritional requirements enterally

#### Order and/or Procedure

The RD will order vital signs, monitoring parameters and lab investigations as outlined in the PN order set (Appendix A), and Order table form.

The RD will select the type of amino acid, dextrose and/or lipid solutions, including custom additives if applicable, volume, rate and route as indicated in the PN order set (<u>Appendix A</u>) and <u>Order table form</u>. The RD will monitor and/or adjust therapy on an ongoing basis as appropriate.

The RD will discontinue PN and all associated elements in the PN Order set (Appendix A) after consultation with the MRP

#### Indications to the implementation of the Directive

RDs may implement this medical directive when all of the following are met:

- The MRP has entered a consult to the RD as either "dietitian to dose PN", or has selected "parenteral nutrition" from the drop down menu, and/or the RD in collaboration with the MRP have determined PN is an appropriate route for nutrition therapy via electronic or verbal communication
- The RD has completed a nutrition assessment

Document Sponsor/Owner Group: Interprofessional Practice, Date Approved 10FEB2020

Lakeridge Health Page 1 of 12



### Medical Advisory Committee Approved: 28SEPT2023

- Consent has been obtained from the patient or substitute decision maker (SDM)
- A central venous access device (CVAD), peripheral vascular access device (PVAD) or midline catheter is in place, or is ordered/planned for insertion to administer the PN
- The MRP has collaborated with the RD to discontinue the PN (e.g. during rounds)

### Contraindications to the implementation of the Directive

- Consent has not been obtained from the patient or SDM.
- PN is not indicated as per the RD assessment
- No CVAD,PVAD or midline catheter is available or planned/ordered to be inserted for the administration of PN
- The patient has a medical condition that would be adversely affected by PN, see specific contraindications as per the <u>Order Table Form</u>

#### Consent

The RD and/or MRP will obtain informed consent from the patient or SDM prior to the implementation of this medical directive per the *Consent Policy Procedure* 

### **Documentation Requirements**

In addition to standard documentation practices, the RD implementing this Medical Directive must ensure the following is documented in the patient's electronic health record:

- The PN order set will be signed using the order mode of "per medical directive"
- The name of the RD will be the Ordering Provider
- The name of the MRP will be the authorizing provider
- The full name of this medical directive will be outlined in the comment section (e.g. Adult Parenteral Nutrition Medical Directive)

#### **Review/Evaluation Process**

This medical directive will be reviewed every 2 years by Inpatient Clinical Nutrition and Interprofessional Practice.

#### References

Ayers, P. et al (2014) ASPEN Parenteral Nutrition Safety Consensus Recommendations. *Journal of Parenteral and Enteral Nutrition* 28(3) 296-333 DOI: 10.1177/0148607113511992

ASPEN (2017) Management of Parenteral Nutrition in Hospitalized Adult Patients. *Journal of Parenteral and Enteral Nutrition* 41(4) 535-549

DOI: 10.1177/0148607116667060

Lakeridge Health Page 2 of 12



### **Medical Advisory Committee Approved: 28SEPT2023**

Boullata, J.I. et al (2014) ASPEN Clinical Guidelines: Parenteral Nutrition Ordering, Order Review, Compounding, Labeling and Dispensing. *Journal of Parenteral and Enteral Nutrition* 38(3) 334-377

DOI: 10.1177/0148607114521833

Lakeridge Health Page 3 of 12



### **Medical Advisory Committee Approved: 28SEPT2023**

\*\*\*This table must **not** be used independently from this Medical Directive\*\*\*

### **Order Table Form**

Vital signs and monitoring			
Order	Indications	Contraindications	Notes
Vital signs will be assessed per hospital policy	To monitor for refeeding complications		Vital signs are assessed at minimum every 8 hours or per patient care standard
For new onset of fever (temperature greater than or equal to 38C) and or chills/rigors  • The PN will be stopped and the MRP will be notified  • Blood culture and sensitivity (C&S) x2  • D10W will run at the same rate if PN is interrupted  • If purulent discharge at catheter insertion site obtain swab culture	PN is a high risk medication for infection		
Height (once) and weight (weekly)	To ensure calculations of nutritional needs are done with accurate parameters		
Intake and output every shift	To adequately capture fluid intake and output		Intake and output will be captured every shift or per patient care standard

Lakeridge Health Page 4 of 12



# **Medical Advisory Committee Approved: 28SEPT2023**

ly and weekly		
Indications	Contraindications	Notes
To monitor for line infection		
To ensure vitamin K dose is correct		PN formulation may be adjusted per results
To ensure vitamin K dose is correct		PN formulation may be adjusted per results
To ensure that the PN formulation does not require modification		PN formulation may be adjusted per results
To monitor for signs and symptoms of hypoglycemia/hyperglycemia		Frequency may need adjustment for patients on existing point of care glucose testing (POCT) and/or insulin administration regimens  PN formulation may be adjusted per results
To ensure protein administration is appropriate and to monitor renal status		PN formulation may be adjusted per results
To monitor renal status		PN formulation may be adjusted per results
To determine need for cyclic vs continuous PN administration		Adjust carbohydrate delivery as required for fluctuations in liver function  Adjust PN administration timing (cyclic vs continuous) as required per results  Protein total may or may not be
	Indications To monitor for line infection To ensure vitamin K dose is correct  To ensure vitamin K dose is correct  To ensure that the PN formulation does not require modification To monitor for signs and symptoms of hypoglycemia/hyperglycemia  To ensure protein administration is appropriate and to monitor renal status To monitor renal status  To determine need for cyclic vs	Indications To monitor for line infection To ensure vitamin K dose is correct  To ensure vitamin K dose is correct  To ensure that the PN formulation does not require modification To monitor for signs and symptoms of hypoglycemia/hyperglycemia  To ensure protein administration is appropriate and to monitor renal status To monitor renal status  To determine need for cyclic vs

Lakeridge Health Page 5 of 12



# **Medical Advisory Committee Approved: 28SEPT2023**

		Ī	DNIC I C I P C I
			PN formulation may be adjusted per
			results
Albumin	To correct calcium and/or magnesium		PN formulation may be adjusted per
			results
Parenteral Nutrition Triglyceride	To monitor clearance of lipids		PN formulation may be adjusted per
			results
Lab investigations: POCT glu	ucose upon TPN initiation		
Order	Indications	Contraindications	Notes
POCT glucose	To monitor and treat signs and		If POCT glucose frequency is
- Q6h x1st 48h	symptoms of hypoglycemia		already established and conflicts
	, , , , , , , , , , , , , , , , , , , ,		with q6h frequency, Q6h POCT
			testing may be modified
			PN formulation may be adjusted per
			results
Hypoglycemia protocol	To monitor and treat signs and		If hypoglycemia protocol already
,, ,, ,	_		
	, , , , , , , , , , , , , , , , , , ,		de-selected from the order set
Adult TPN Custom Ion Based	3 in 1 formulation		
Order	Indications	Contraindications	Notes
Continuous infusion 25-	Patients not able to meet their	Patient is able to	Dextrose infusion less than or equal
125mL/hr for 24 hours	nutritional needs orally or enterally	meet their	to 7g/kg/d
	·	nutritional	
		requirements	Lipid infusion of no more than
		enterally	1g/kg/d or less than 30% of daily
			kcal
			If osmolarity is equal to or less than
			900mOsm/Ĺ, a PVAD or midline
			may be used; if osmolarity is greater
Adult TPN Custom Ion Based Order Continuous infusion 25-	symptoms of hypoglycemia  3 in 1 formulation Indications Patients not able to meet their	Patient is able to meet their nutritional requirements	ordered for the patient, this may be de-selected from the order set  Notes  Dextrose infusion less than or equa to 7g/kg/d  Lipid infusion of no more than 1g/kg/d or less than 30% of daily kcal  If osmolarity is equal to or less than 900mOsm/L, a PVAD or midline

Lakeridge Health Page 6 of 12



# **Medical Advisory Committee Approved: 28SEPT2023**

Cyclic infusion parenteral solution 25-200mL/hr for less than 24 hours	Patients not able to meet their nutritional needs orally or enterally	Patient is able to meet their nutritional	than 900mOsm/L only a CVAD may be used for administration Dextrose infusion rate of no more than 7g/kg/d
than 24 hours	Abnormal liver function  Planning for discharge home  Increasing ambulation	requirements enterally	Lipid infusion of no more than 1 g/kg/d *higher doses (up to 1.5g/kg/d) of composite lipid emulsion containing fish oil may be well tolerated with reduced hepatic complications  If osmolarity is less than 900mOsm/L, a PVAD or midline may be used; if osmolarity is greater than 900mOsm/L only a CVAD may be used for administration
Amino Acids			
Order	Indications	Contraindications	Notes
Travasol 10% Protein 0.8-2g/kg	Provision of protein in patients not able to meet their protein needs orally or enterally	Congenital abnormality of amino acid metabolism  Patient is able to meet their nutritional requirements enterally	Content/L: 100g protein, 16.8g Nitrogen (400kcal)  If osmolarity is less than 900mOsm/L, a PVAD or midline may be used; if osmolarity is greater than 900mOsm/L only a CVAD may be used for administration

Lakeridge Health Page 7 of 12



# **Medical Advisory Committee Approved: 28SEPT2023**

Prosol 20%	Provision of protein in patients not able to meet their protein needs orally or enterally	Congenital abnormality of amino acid metabolism  Patient is able to meet their nutritional requirements enterally	Content/L: 200g protein, 32.1g Nitrogen, (800 kcal)  If osmolarity is less than 900mOsm/L, a PVAD or midline may be used; if osmolarity is greater than 900mOsm/L only a CVAD may be used for administration
Dextrose Order	Indications	Contraindications	Notes
Dextrose 0-700g	Provision of energy in patients unable to meet their energy needs orally or enterally		Dextrose grams are determined based on total energy needs (kcal/day) and proportion of carbohydrates required for the total solution  Pharmacy converts dextrose grams to a percentage to determine percent of dextrose as the base solution  If osmolarity is less than 900mOsm/L, a PVAD or midline may be used; if osmolarity is greater than 900mOsm/L only a CVAD may be used for administration
Lipids	1		
Order	Indications	Contraindications	Notes
SMOF lipid SMOF Lipid at 0-25mL/h	Provision of energy and essential fatty acids requirements in patients not able	Allergy to fish, soy, egg or peanuts	Clarify allergies; if true allergy to fish, use Intralipid



# **Medical Advisory Committee Approved: 28SEPT2023**

	to meet their nutritional needs orally or enterally		May be administered via CVAD, PVAD or midline catheter
Intralipid Intralipid at 0-15mL/h	Provision of energy and essential fatty acids requirements in patients not able to meet their nutritional needs orally or enterally		Use if patient has severe fish, egg, or soy allergy. The RD may need to complete an additional risk assessment and collaborate with the MRP
			Lipid infusion of no more than 1 g/kg/d
			May be administered via CVAD, PVAD or midline catheter
Electrolytes			PVAD of midline catheter
Order	Indications	Contraindications	Notes
Sodium (Na)	To provide daily electrolyte	NA	PN formulation may be adjusted per
0-4 mmol/kg per 24 hours	requirements		blood work results
Potassium (K+)	To provide daily electrolyte	NA	PN formulation may be adjusted per
0-4 mmol/kg per 24 hours	requirements		blood work results
Magnesium (Mg)	To provide daily electrolyte	NA	PN formulation may be adjusted per
0-25 mmol/kg per 24 hours	requirements		blood work results
Calcium (Ca)	To provide daily electrolyte	NA	PN formulation may be adjusted per
0-15 mmol/kg per 24 hours	requirements		blood work results
Phosphate (PO4)	To provide daily electrolyte	NA	PN formulation may be adjusted per
0-60 mmol per 24 hours	requirements		blood work results
Trace elements	To provide daily trace mineral	NA	PN formulation may be adjusted per
0-1 mL per 24 hours	requirements		blood work results
Multivitamins (Multi12)	To provide daily vitamin requirements	NA	If already receiving multivitamins
0-10 mL per 24 hours			there may not be a need via PN
Phytonadione Vitamin K	To provide adequate vitamin K requirements	Abnormal INR	Weekly vitamin K may or may not be ordered for patients on ongoing

Lakeridge Health Page 9 of 12



# **Medical Advisory Committee Approved: 28SEPT2023**

0-3 mg IV minibag once per week, as per PN order set  Thiamine (first dose administered prior to starting PN 100-500mg IV daily x 3 – 7 days	To mitigate risk of refeeding syndrome;  If Thiamine deficiency expected	Patient meeting Vitamin K needs through alternate source Patient with documented allergy to thiamine Patient has pre- existing thiamine orders	warfarin therapy; Consultation with pharmacy can occur as required for a daily dose.  Could be ordered beyond 7 days for severe malnutrition	
Chloride Acetate Ratio	To balance serum chloride and serum bicarbonate		PN formulation may be adjusted per blood work results	
<b>Adult TPN Commercial Prem</b>	Adult TPN Commercial Premixed Solution 3 in 1 formulation: After Hours			
Order	Indications	Contraindications	Notes	
Continuous infusion 25- 125mL/hr for 24 hours	Patients not able to meet their nutritional needs orally or enterally	Patient is able to meet their nutritional requirements enterally	Dextrose infusion less than or equal to 7g/kg/d  Lipid infusion of no more than 1g/kg/d or less than 30% of daily kcal  Osmolarity for commercially premixed solutions is equal to or less than 900mOsm/L and may be administered via PVAD, midline or CVAD	
Cyclic infusion parenteral solution 25-200mL/hr for less than 24 hours	Patients not able to meet their nutritional needs orally or enterally  Abnormal liver function	Patient is able to meet their nutritional requirements enterally	Dextrose infusion rate of no more than 7g/kg/d  Lipid infusion of no more than 1 g/kg/d *higher doses (up to	

Lakeridge Health Page 10 of 12



# **Medical Advisory Committee Approved: 28SEPT2023**

	Planning for discharge home Increasing ambulation		1.5g/kg/d) of composite lipid emulsion containing fish oil may be well tolerated with reduced hepatic complications
			Osmolarity for commercially premixed solutions is equal to or less than 900mOsm/L and may be administered via PVAD, midline or CVAD
SMOF Kabiven 3.2% Amino Acid, 7.1% Dextrose, 2.8% Lipid	Patients not able to meet their nutritional needs orally or enterally	Patient is able to meet their nutritional	The cut-off time for customized PN formulations is 1200pm
	The patient required parenteral nutrition after the cut-off time for custom PN	requirements enterally	Anhydrous Dextrose provides 4kcal/g in this solution
			Osmolarity for commercially premixed solutions is equal to or
			less than 900mOsm/L and may be
			administered via PVAD, midline or CVAD

Lakeridge Health Page 11 of 12



### **Medical Advisory Committee Approved: 28SEPT2023**

### Appendix A

Order set name	Orders		
IP total Parenteral	Nursing		
Nutrition (TPN)	Vital signs and monitoring		
	<ul> <li>Fever management, height and weight, intake and output,</li> </ul>		
	Lab investigations (initial)		
	CBC and differential, APTT, INR/PT, Electrolytes, glucose, calcium, magnesium, phosphate, albumin,		
	parenteral nutrition triglyceride, osmolarity		
	Liver function panel		
	<ul> <li>Protein total, albumin, bilirubin total, alkaline phosphate (ALP), alanine aminotransferase (ALT)</li> </ul>		
	Lab investigations POCT glucose upon TPN initiation		
	Lab investigations (daily)		
	Lab investigations (weekly)		
	Medications		
	PN: AA, Dextrose, Lipids		
	After hours		
	Additional medications		
	Phytonadione (vitamin K1)		
	Thiamine		

Lakeridge Health Page 12 of 12